Literature DB >> 9795106

Cyclosporin inhibition of apoptosis induced by mitochondrial complex I toxins.

T A Seaton1, J M Cooper, A H Schapira.   

Abstract

The cause of dopaminergic cell death in Parkinson's disease (PD) remains unknown, but may involve oxidative stress and mitochondrial complex I deficiency. Opening of the permeability transition pore and disruption of the mitochondrial transmembrane potential are known to be common events in the apoptotic pathway. Cyclosporin A and its non-immunosuppressant analogue, N-methyl-4-valine cyclosporin inhibit the opening of the mitochondrial megachannel. Complex I inhibitors, including MPP+, are known to induce both apoptosis in cell culture and parkinsonism in man and other primates. The present study using propidium iodide and FITC-TUNEL staining to identify apoptotic cells, demonstrates that rotenone, MPP+ and tetrahydroisoquinoline induce apoptosis in PC12 cells. Apoptosis induced by these agents was decreased by cyclosporin A and N-methyl-4-valine cyclosporin. Thus, apoptosis induced by inhibitors of mitochondrial complex I is probably mediated by permeability pore opening and collapse of the mitochondrial membrane potential. This observation may allow the development of novel neuroprotective strategies in disorders that may involve mitochondrial dysfunction and apoptotic cell death. Copyright 1998 Elsevier Science B.V.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9795106     DOI: 10.1016/s0006-8993(98)00790-2

Source DB:  PubMed          Journal:  Brain Res        ISSN: 0006-8993            Impact factor:   3.252


  23 in total

Review 1.  Monoamine oxidase B inhibitors for the treatment of Parkinson's disease: a review of symptomatic and potential disease-modifying effects.

Authors:  Anthony H V Schapira
Journal:  CNS Drugs       Date:  2011-12-01       Impact factor: 5.749

2.  Differential involvement of mitochondrial permeability transition in cytotoxicity of 1-methyl-4-phenylpyridinium and 6-hydroxydopamine.

Authors:  Chung Soo Lee; Woo Jae Park; Hyun Hee Ko; Eun Sook Han
Journal:  Mol Cell Biochem       Date:  2006-04-20       Impact factor: 3.396

Review 3.  The mitochondrial permeability transition in neurologic disease.

Authors:  M D Norenberg; K V Rama Rao
Journal:  Neurochem Int       Date:  2007-03-04       Impact factor: 3.921

4.  Depressant effect of mitochondrial respiratory complex inhibitors on proteasome inhibitor-induced mitochondrial dysfunction and cell death in PC12 cells.

Authors:  Sun-Joo Lee; Young Chul Youn; Eun Sook Han; Chung Soo Lee
Journal:  Neurochem Res       Date:  2005-09       Impact factor: 3.996

5.  Proteolytic regulation of the mitochondrial cAMP-dependent protein kinase.

Authors:  Jennifer R Shell; David S Lawrence
Journal:  Biochemistry       Date:  2012-03-08       Impact factor: 3.162

6.  Neutrophil adhesion to vascular prosthetic surfaces triggers nonapoptotic cell death.

Authors:  G S Nadzam; C De La Cruz; R S Greco; B Haimovich
Journal:  Ann Surg       Date:  2000-04       Impact factor: 12.969

7.  MicroRNA-7 inhibits neuronal apoptosis in a cellular Parkinson's disease model by targeting Bax and Sirt2.

Authors:  Shize Li; Xuecheng Lv; Kaihua Zhai; Ruyan Xu; Yong Zhang; Songyao Zhao; Xiaoming Qin; Liujie Yin; Jiyu Lou
Journal:  Am J Transl Res       Date:  2016-02-15       Impact factor: 4.060

Review 8.  The molecular composition of the mitochondrial permeability transition pore.

Authors:  Christopher P Baines
Journal:  J Mol Cell Cardiol       Date:  2009-02-20       Impact factor: 5.000

9.  An in vitro model of Parkinson's disease: linking mitochondrial impairment to altered alpha-synuclein metabolism and oxidative damage.

Authors:  Todd B Sherer; Ranjita Betarbet; Amy K Stout; Serena Lund; Melisa Baptista; Alexander V Panov; Mark R Cookson; J Timothy Greenamyre
Journal:  J Neurosci       Date:  2002-08-15       Impact factor: 6.167

Review 10.  Role of mitochondrial dysfunction in the pathogenesis of Huntington's disease.

Authors:  Rodrigo A Quintanilla; Gail V W Johnson
Journal:  Brain Res Bull       Date:  2009-07-19       Impact factor: 4.077

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.